Here’s a thought experiment: take every fact asserted and every quote offered in this article about HGH use and testing in the NFL and replace the proper nouns with baseball players and baseball teams. And then ask yourself how thick the walls would have to be on your backyard shelter to withstand the nuclear fallout from all of the outrage that would come from the sporting press:
As soon as the three letters are mentioned – H-G-H – the player laughs. Human growth hormone? In the NFL? Come on. HGH use is rampant, this NFC starter says. “It’s like clockwork nowadays,” he said, estimating 10-15 players on each team use the banned substance. “Not tested and it’s easy to get. Nowadays, dude? In 2013? (Expletive) yeah. I’m just being real.” …
… Twenty-one months after agreeing to a test, HGH remains a part of the NFL. That’s the cold, unsettling reality. “Until they start testing for it, it’s not illegal, right?” [Darren] Woodson said. “It’s just a dirty game. I’ve always felt it was that way.”
Thing is, a lot of people in that article make good points about the use and efficacy of HGH. But you’re not allowed to talk about that in baseball. Orthodoxy mandates that HGH is evil, squeezed from The Devil’s glands and used only by those of blackest heart. And they turn you from a crappy player to a Hall of Famer overnight. Except the Hall of Fame part, because we won’t have you there if you dare use HGH.
Why does football get to actually talk about this stuff? Why aren’t any sportswriters giving up on football and damning that whole lot to Hell?
For the next day and a half you’ll hear a lot about the non-tender deadline and/or players being tendered or not tendered a contract. Here, in case you’re unaware, is what that means.
By midnight on Wednesday teams have to decide whether to tender contracts to arbitration-eligible players. If they do, the team retains control over the player. Now, to be clear, the team is not simply “tendering” the player the actual contract specifying what he’ll be paid. Think of it as more of a token gesture — a placeholder contract — at that point the team and the player can negotiate salary for 2016 and, if they can’t come to an agreement over that (i.e. an agreement avoiding arbitration) they will proceed to submit proposed salaries to one another and have a salary arbitration early in the spring.
If the team non-tenders a player, however, that player immediately becomes a free agent, eligible to sign anywhere with no strings attached.
Basically, the calculus is whether or not the team thinks the player in question is worth the low end of what he might receive in arbitration. Or, put differently, if the guy isn’t worth what he made in 2015, he’s probably going to be non-tendered.
MLB Trade Rumors has a handy “Non-Tender Tracker” which lists the status of the couple hundred arbitration eligible players and whether or not they’ve been tendered a contract. We’ll, of course, make mention of notable non-tender guys as their status for 2016 becomes known over the next day or two.
New Mariners general manager Jerry Dipoto has kept pretty busy in his short time on the job and Bob Dutton of the Tacoma News Tribune reports that free agent outfielder Nori Aoki could be his next target. The club recently pursued a trade for Marlins outfielder Marcell Ozuna, but the asking price has them looking at alternatives.
Aoki, who turns 34 in January, has hit .287 with a .353 on-base percentage over four seasons since coming over from Japan. He was having a fine season with the Giants this year prior to being shut down in September with lingering concussion symptoms.
The Giants decided against picking up Aoki’s $5.5 million club option for 2016 earlier this month, but he should still do pretty well for himself this winter assuming he’s feeling good.
It was reported Sunday that free agent right-hander Johnny Cueto had turned down a six-year, $120 million contract from the Diamondbacks. He’s hoping to land a bigger deal this winter and ESPN’s Jerry Crasnick has heard some chatter about what he’s looking for.
Jordan Zimmermann finalized a five-year, $110 million contract with the Tigers today, which works out to $22 million per season. Arizona’s offer to Cueto checked in at $20 million per season. A six-year offer to Cueto at the same AAV (average annual value) as Zimmermann would put him at $132 million, which is still a little shy of the figure stated by Crasnick. Of course, Cueto owns a 2.71 ERA (145 ERA+) over the last five seasons compared to a 3.14 ERA (123 ERA+) by Zimmermann during that same timespan, so there’s a case to be made that he should get more. Still, he’s the clear No. 3 starter on the market behind David Price and Zack Greinke.
CBS Sports’ Jon Heyman reports that the Dodgers, Giants, Red Sox, and Cubs are among the other teams who have interest in Cueto. One variable in his favor is that he is not attached to draft pick compensation, as he was traded from the Reds to the Royals during the 2015 season.
The rebuilding Braves have already been active on the trade market and they might not be done, as CBS Sports’ Jon Heyman reports that right-hander Shelby Miller has been a very popular name. In fact, around 20 teams have checked in.
Nothing is considered close and the Braves have set a very high asking price, mostly centered around offense. They asked for right-hander Luis Severino in talks with the Yankees and would expect outfielder Marcell Ozuna among other pieces from the Marlins. The Diamondbacks and Giants are among the other interested clubs.
Miller is under team control through 2018, so there’s not necessarily a sense of urgency to move him, but anything is possible with the way the Braves are doing things right now. The 25-year-old is coming off a year where he went 6-17, but that was about really rotten luck more than anything else, as he had a fine 3.02 ERA and 171/73 K/BB ratio over 205 1/3 innings. The Braves gave him the worst run support of any starter in the majors.